Magrey M, Yi E, Wolin D, Price M, Chirila C, Davenport E, Park Y. Understanding barriers in the pathway to diagnosis of ankylosing spondylitis: results from a US survey of 1690 physicians from 10 specialties. ACR Open Rheumatol. 2020 Oct;2(10):616-26. doi: 10.1002/acr2.11179
Saigi-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Choong E, Gholamrezaee M, Magistretti P, Aubry JM, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Kutalik Z, Conus P, Eap CB. Association of PCK1 with body mass index and other metabolic features in patients with psychotropic treatments. J Clin Psychopharmacol. 2015 Oct;35(5):544-52. doi: 10.1097/JCP.0000000000000388
Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, Schneeweiss S. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012 Feb 1;32(1):11-7.
Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.
Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, Worgan AD. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002 Mar;13(1):167-76.
Quittner AL, Sweeny S, Watrous M, Munzenberger P, Bearss K, Gibson NA, Fisher LA, Henry B. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol. 2000 Sep 1;25(6):403-14.